Evidence map›Paper›PMID 24886416›Full record

ArticleVirology journal2014

Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I.

Sonia Shah, Aikaterini Alexaki, Vanessa Pirrone, Satinder Dahiya, Michael R Nonnemacher, Brian Wigdahl

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  6. Review
  7. Article
  8. Article
  9. Genetic variation and function of the HIV-1 Tat protein.Medical microbiology and immunology · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sonia Shah
Aikaterini Alexaki
Vanessa Pirrone
Satinder Dahiya
Michael R Nonnemacher
Brian WigdahlDepartment of Microbiology and Immunology, and Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA. bwigdahl@drexelmed.edu.
Drexel University · USInstitute for Molecular Medicine · US

Funding

Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
High Specificity HIV-1 Markers Predictive of Neuro-AIDSR01DA019807 · NIDA · DREXEL UNIVERSITY · PI WIGDAHL, BRIAN · 2004 to 2014
$5.1M
NEUROLOGICAL &LYMPHOID FACTORS IN HIV1 LTR ACTIVATIONR01NS032092 · NINDS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI WIGDAHL, BRIAN · 1993 to 2011
$3.9M
Co-evolution of HIV-1 Regulators in CNS DiseaseR01NS046263 · NINDS · DREXEL UNIVERSITY · PI WIGDAHL, BRIAN · 2004 to 2009
$1.8M
NIDA NIH HHS DA19807NIMH NIH HHS 5T32MH079785NINDS NIH HHS NS32092NINDS NIH HHS NS46263
6 · The paper itself

Abstract

backgroundHIV-1 gene expression is driven by the long terminal repeat (LTR), which contains many binding sites shown to interact with an array of host and viral factors. Selective pressures within the host as well as the low fidelity of reverse transcriptase lead to changes in the relative prevalence of genetic variants within the HIV-1 genome, including the LTR, resulting in viral quasispecies that can be differentially regulated and can potentially establish niches within specific cell types and tissues.

methodsUtilizing flow cytometry and electromobility shift assays, specific single-nucleotide sequence polymorphisms (SNPs) were shown to alter both the phenotype of LTR-driven transcription and reactivation. Additional studies also demonstrated differential loading of transcription factors to probes derived from the double-variant LTR as compared to probes from the wild type.

resultsThis study has identified specific SNPs within CCAAT/enhancer binding protein (C/EBP) site I and Sp site III (3 T, C-to-T change at position 3, and 5 T, C-to-T change at position 5 of the binding site, respectively) that alter LTR-driven gene transcription and may alter the course of viral latency and reactivation. The HIV-1 LAI LTRs containing the SNPs of interest were coupled to a plasmid encoding green fluorescent protein (GFP), and polyclonal HIV-1 LTR-GFP stable cell lines utilizing bone marrow progenitor, T, and monocytic cell lines were constructed and utilized to explore the LTR phenotype associated with these genotypic changes.

conclusionsAlthough the 3 T and 5 T SNPs have been shown to be low-affinity binding sites, the fact that they can still result in effective HIV-1 LTR-driven gene expression, particularly within the TF-1 cell line, has suggested that the low binding site affinities associated with the 3 T C/EBP site I and 5 T Sp site III are potentially compensated for by the interaction of nuclear factor-κB with its corresponding binding sites under selected physiological and cellular conditions. Additionally, tumor necrosis factor-α and Tat can enhance basal transcription of each SNP-specific HIV-1 LTR; however, differential regulation of the LTR is both SNP- and cell type-specific.

Indexed as

Polymorphism, Single NucleotideCCAAT-Enhancer-Binding ProteinsCell LineElectrophoretic Mobility Shift AssayFlow CytometryHIV-1HIV Long Terminal RepeatHumansProtein BindingSp1 Transcription FactorTranscription, GeneticVirus ActivationCCAAT-Enhancer-Binding ProteinsSP1 protein, humanSp1 Transcription Factor

Identifiers

PMID24886416
PMCPMC4047001
OpenAlexW2126366098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.